Justyna Bartoszko

Dr. Justyna Bartoszko


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
JBJustyna Bartoszko
Justyna Bartoszko
KKKeyvan Karkouti
Keyvan Karkouti

21 April 2021 in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Verified
Journal Article
Closed access
PDF file
CHCiara Hanley
Ciara Hanley
JCJeannie Callum
Jeannie Callum
KKKeyvan Karkouti
Keyvan Karkouti
JBJustyna Bartoszko
Justyna Bartoszko

14 September 2021 in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Verified
Journal Article
Open access
PDF file
JBJustyna Bartoszko
Justyna Bartoszko
JCJeannie Callum
Jeannie Callum
KKKeyvan Karkouti
Keyvan Karkouti
TIthe FIBRES study investigators
the FIBRES study investigators
Purpose The mainstay of therapy for coagulation factor deficiency in cardiac surgical patients is frozen plasma (FP); however, prothrombin complex concentrates (PCCs) may offer logistical and safety advantages. As there is limited comparative evidence, we conducted this study to explore the association of comparable PCC or FP doses with transfusion and outcomes. Methods This was a post hoc analysis of a multicentre randomized trial comparing fibrinogen concentrate with cryoprecipitate (FIBRES trial) in bleeding cardiac surgical patients. This analysis included 415 patients who received only PCC (n = 72; 17%) or only FP (n = 343; 83%) for factor replacement. The main outcomes of interest were red blood cell (RBC) and platelet transfusion within 24 hr of cardiopulmonary bypass. Secondary outcomes included postoperative adverse events. Associations were examined by hierarchical generalized estimating equation models adjusted for demographic and surgical characteristics. Results The median [interquartile range (IQR)] PCC dose was 1,000 [1,000–2,000] units, while the median [IQR] FP dose was 4 [2–6] units. Each unit of FP was independently associated with increased adjusted odds of RBC (1.60; 95% confidence interval [CI], 1.36 to 1.87; P < 0.01) and platelet transfusion (1.40; 95% CI, 1.15 to 1.69; P < 0.01) while each 500 units of PCC was independently associated with reduced adjusted odds of RBC (0.67; 95% CI, 0.50 to 0.90; P < 0.01) and platelet transfusion (0.80; 95% CI, 0.70 to 0.92; P < 0.01). Adverse event rates were comparable. Conclusions In cardiac surgical patients with post-cardiopulmonary bypass bleeding, PCC use was associated with lower RBC and platelet transfusion than FP use was. Prospective, randomized clinical trials comparing FP with PCC in this setting are warranted.

28 November 2023 in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Verified
Journal Article
Closed access
PDF file
MLMichelle M. Li
Michelle M. Li
SMSarah Miles
Sarah Miles
JCJeannie Callum
Jeannie Callum
YLYulia Lin
Yulia Lin
KKKeyvan Karkouti
Keyvan Karkouti
JBJustyna Bartoszko
Justyna Bartoszko

22 December 2021 in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Verified
Journal Article
Closed access
PDF file
JBJustyna Bartoszko
Justyna Bartoszko
HLHan Li
Han Li
JFJohn Fitzgerald
John Fitzgerald
LHLoretta T. S. Ho
Loretta T. S. Ho
CSCyril Serrick
Cyril Serrick
KKKeyvan Karkouti
Keyvan Karkouti

28 June 2022 in British Journal of Anaesthesia
Verified
Journal Article
Open access
JBJustyna Bartoszko
Justyna Bartoszko
SMSelene Martinez-Perez
Selene Martinez-Perez
JCJeannie Callum
Jeannie Callum
KKKeyvan Karkouti
Keyvan Karkouti
MFMichael E. Farouh
Michael E. Farouh
MZMichelle Zeller
Michelle Zeller
Coagulopathy in cardiac surgery is frequently associated with acquired hypofibrinogenaemia, which can be treated with either purified fibrinogen concentrate (FC) or cryoprecipitate. Because the latter is not purified and therefore contains additional coagulation factors, it is thought to be more effective for treatment of coagulopathy that occurs after prolonged cardiopulmonary bypass (CPB). We examined the impact of CPB duration on the efficacy of the two therapies in cardiac surgery. This was a post hoc analysis of the Fibrinogen Replenishment in Surgery (FIBRES) RCT comparing FC (4 g) to cryoprecipitate (10 U) in adult patients undergoing cardiac surgery and experiencing bleeding with acquired hypofibrinogenaemia (n=735). The primary outcome was allogeneic blood products transfused within 24 h after CPB. Subjects were stratified by CPB duration (≤120, 121-180, and >180 min). The interaction of treatment assignment with CPB duration was tested. Subjects with longer CPB duration experienced more bleeding and transfusion. With CPB time ≤120 min (FC, n=134; cryoprecipitate, n=146), the ratio of least-squares means between the FC and cryoprecipitate groups for total allogeneic blood products at 24 h was 0.90 (one-sided 97.5% confidence interval [CI]: 0.00-1.12); P=0.004. For subjects with CPB time 121-180 min, it was 1.00 ([one-sided 97.5% CI: 0.00-1.22]; P=0.03], and for CPB time >180 min it was 0.91 ([one-sided 97.5% CI: 0.00-1.12]; P=0.005). Results were similar for all secondary outcomes, with no interaction between treatment and CPB duration for all outcomes. The haemostatic efficacy of FC was non-inferior to cryoprecipitate irrespective of CPB duration in cardiac surgery. NCT03037424.